Literature DB >> 20169546

TTP disease course is independent of myeloma treatment and response.

Craig C Hofmeister, Ming Jin, Spero R Cataland, Don M Benson, Haifeng M Wu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20169546      PMCID： PMC3557928          DOI： 10.1002/ajh.21646

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  11 in total

1.  Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases.

Authors:  M Kornacker; T Luft; A D Ho; H-J Schaefer
Journal:  Eur J Haematol       Date:  2005-03       Impact factor: 2.997

2.  An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.

Authors:  Spero R Cataland; Ming Jin; Amy K Ferketich; Melanie S Kennedy; Eric H Kraut; James N George; Haifeng M Wu
Journal:  Br J Haematol       Date:  2006-10-27       Impact factor: 6.998

3.  von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.

Authors:  R M van der Plas; M E Schiphorst; E G Huizinga; R J Hené; L F Verdonck; J J Sixma; R Fijnheer
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

4.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

5.  A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry.

Authors:  M Jin; S Cataland; M Bissell; H M Wu
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

6.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

7.  Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.

Authors:  Richard K Burt; Yvonne Loh; Bruce Cohen; Dusan Stefoski; Dusan Stefosky; Roumen Balabanov; George Katsamakis; Yu Oyama; Eric J Russell; Jessica Stern; Paolo Muraro; John Rose; Alessandro Testori; Jurate Bucha; Borko Jovanovic; Francesca Milanetti; Jan Storek; Julio C Voltarelli; William H Burns
Journal:  Lancet Neurol       Date:  2009-01-29       Impact factor: 44.182

8.  Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity.

Authors:  Spero R Cataland; Ming Jin; Shili Lin; Melanie S Kennedy; Eric H Kraut; James N George; Haifeng M Wu
Journal:  Br J Haematol       Date:  2007-11       Impact factor: 6.998

9.  Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation.

Authors:  R Sarode; J G McFarland; N Flomenberg; J T Casper; E P Cohen; W R Drobyski; R C Ash; M M Horowitz; B Camitta; C Lawton
Journal:  Bone Marrow Transplant       Date:  1995-08       Impact factor: 5.483

10.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.

Authors:  Jing-fei Dong; Joel L Moake; Leticia Nolasco; Aubrey Bernardo; Wendy Arceneaux; Corie N Shrimpton; Alicia J Schade; Larry V McIntire; Kazuo Fujikawa; José A López
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113
View more
  4 in total

1.  Thrombotic thrombocytopenic purpura as initial and major presentation of multiple myeloma.

Authors:  Xiang Xiao; Hai-ying Zhong; Guang-sen Zhang; Ming-yang Deng
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

Review 2.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

Review 3.  Kidney injury and disease in patients with haematological malignancies.

Authors:  Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung
Journal:  Nat Rev Nephrol       Date:  2021-03-30       Impact factor: 28.314

Review 4.  How I treat microangiopathic hemolytic anemia in patients with cancer.

Authors:  M R Thomas; M Scully
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.